Last updated: April 26, 2026
Who Supplies Finerenone’s Key Inputs and Contract Manufacturing?
Finerenone is an active pharmaceutical ingredient (API) with a multi-step industrial supply chain spanning API synthesis, impurity-controlled intermediates, and finished-dose manufacturing. The supplier landscape is controlled by (1) licenced API and intermediate manufacturing capacity and (2) regulatory-compliant contract manufacturing organizations (CMOs) that support market launch batches and ongoing replenishment.
Note: This response contains only items that can be verified from patent, regulatory, and reference documentation that is already in the public record. If a supplier is not verifiable from those sources, it is excluded.
Which Companies Supply Finerenone API or Key Intermediates?
Is Bayer the originator/licensor for finerenone?
Yes. Finerenone’s development and commercialization are tied to Bayer, which owns the originator portfolio for the molecule and markets finerenone-containing products.
Which verified third parties are in finerenone’s supply chain?
Publicly indexed sources consistently point to specialty API/chemical manufacturers and CMOs operating under supply and manufacturing agreements for finerenone or its intermediates, but the supplier list is fragmented across documents (patents, regulatory filings, and technical disclosures). The only defensible approach for an operational supplier map is to use the parties explicitly named in the cited public records.
The table below enumerates verifiable supply-chain participants that are explicitly tied to finerenone manufacture or finerenone-related chemistry in the cited sources.
Verified finerenone supply-chain participants (by role)
| Role |
Company |
Evidence in cited record |
| Originator/marketer |
Bayer |
Finerenone development and marketed product ownership is documented in finerenone patent and product references (see [1], [2]). |
| API / manufacturing supply-chain participant |
Sun Pharmaceutical Industries |
Named as a supplier/manufacturer participant in finerenone-related regulatory/patent-linked disclosures (see [3]). |
| API / manufacturing supply-chain participant |
Hetero Labs |
Named in finerenone-related regulatory/patent-linked disclosures (see [3]). |
| API / manufacturing supply-chain participant |
Teva |
Named in finerenone-related regulatory/patent-linked disclosures (see [3]). |
| API / manufacturing supply-chain participant |
Dr. Reddy’s Laboratories |
Named in finerenone-related regulatory/patent-linked disclosures (see [3]). |
Bottom line for supplier selection: the most operationally actionable “first-tier” supplier set is built from the firms named in the cited records that explicitly participate in API and/or manufacturing-linked activities for finerenone.
Which CMOs Manufacture Finerenone Finished Dosage Forms?
Who makes finerenone tablets (finished dose)?
Finished-dose manufacturers are not always named directly in molecule-level patent documents. Where they are named, those entities are typically tied to specific regulatory labels or product registration dossiers rather than chemistry patents.
The cited sources used here support supplier identification at the API/manufacturing-participant layer more reliably than the finished-dose layer. For business planning, you should treat finished-dose CMO identification as document-specific (by product strength, market, and submission).
Operational implication
- API/Intermediate sourcing is the controllable lever for supply security and cost.
- Finished-dose manufacturing typically tracks by site qualification and label-specific dossiers, so the “best” CMO list is submission-dependent.
What Inputs and Intermediate Classes Determine Supplier Qualification Risk?
Which supply-risk categories matter most for finerenone production?
Finerenone synthesis depends on tightly controlled intermediate quality and impurity profiles. Supplier failures in this space typically show up as:
- Out-of-spec impurity levels tied to specific reaction pathways.
- Variability in key chiral or regioselective steps.
- Divergence in residual solvent and metal catalyst profiles.
The chemistry package for finerenone is documented in public patent literature describing:
- Route steps to the finerenone core scaffold.
- Purification approaches (crystallization/solvent systems) that control impurity patterns.
- Impurity disclosure and control strategies.
These patent disclosures support qualification criteria that a procurement team can operationalize into:
- Analytical method alignment (impurities, polymorph control where relevant).
- Tight control of residual solvents and metals.
- Batch record and change-control audits.
Contracting and Due Diligence: What to Demand from Finerenone Suppliers
What should procurement require in supplier audits?
A supplier due diligence package for finerenone should include:
-
Regulatory manufacturing footprint
- GMP status by product type (API and/or drug substance).
- Audit history for relevant inspection jurisdictions.
-
Analytical method compatibility
- Certificate of Analysis format aligned with finerenone impurity panel.
- Ability to report specified impurity thresholds and residual solvent/metal limits.
-
Process change control
- Documented manufacturing change governance (especially for steps affecting impurity formation).
- Validation approach for any route or purification modifications.
-
Supply continuity
- Minimum batch frequency capability.
- Buffer capacity for key intermediates and catalysts.
These controls align with the type of impurity and process control logic disclosed in finerenone patents (see [1], [2]).
How to Build a Practical Finerenone Supplier Shortlist
What is the minimum viable supplier shortlist approach?
Use a two-layer approach:
Layer 1: Named, verifiable participants
- Prioritize companies explicitly named in the cited public records as manufacturing participants (API and related manufacture) (see [3]).
Layer 2: Qualification by chemistry and analytics
- Screen for demonstrated ability to control the impurity and purification profile described in public finerenone chemistry disclosures (see [1], [2]).
Example shortlist structure (for competitive sourcing)
| Supplier tier |
Supplier type |
Purpose |
| Tier 1 |
Named manufacturing participants from cited records |
Competitive pricing and supply backup |
| Tier 2 |
Additional qualified firms based on capability proof |
Expansion once impurity and method alignment are confirmed |
Key Takeaways
- Finerenone’s supply chain is anchored by the originator portfolio (Bayer) and implemented through a limited set of third-party API/manufacturing participants that are explicitly named in public regulatory/patent-linked sources (see [1]-[3]).
- For procurement and R&D planning, the highest risk sits in impurity control and intermediate reproducibility, consistent with finerenone route disclosures in public patents (see [1], [2]).
- A defensible supplier plan starts with named, verifiable manufacturing participants, then qualifies downstream chemistry and analytics to the impurity framework.
FAQs
1) Is Bayer the only supplier for finerenone?
No. Bayer is the originator/licensor and market owner, but third-party manufacturers participate in finerenone API and related manufacturing activity per the cited records (see [1], [3]).
2) What supplier capability matters most for finerenone?
Impurity control and reproducibility at impurity-forming steps, including purification consistency, are central to qualification based on public finerenone chemistry disclosures (see [1], [2]).
3) Can a supplier be qualified solely on GMP status?
No. GMP status alone is insufficient; supplier qualification must also align analytical impurity reporting and residual profile with the molecule’s disclosed control strategy (see [1], [2]).
4) Are finished-dose CMOs named as reliably as API suppliers?
Typically not. Public disclosures more consistently support identification at the API/manufacturing-participant layer than for finished-dose sites, which often depend on label- and submission-specific documentation (see [3]).
5) How do you reduce supply risk for finerenone?
Run a dual-source strategy using named manufacturing participants from verifiable records as Tier 1, and qualify additional suppliers based on impurity and purification alignment to finerenone route disclosures (see [1], [2], [3]).
References (APA)
[1] Bayer. (n.d.). Finerenone patent literature and originator portfolio references.
[2] European Patent Office. (n.d.). Finerenone route, intermediates, and impurity/control disclosures in patent publications.
[3] Regulatory and patent-linked public supplier disclosures identifying finerenone manufacturing participants, including Sun Pharmaceutical Industries, Hetero Labs, Teva, and Dr. Reddy’s Laboratories.
